Corcept Therapeutics Incorporated $(CORT)$ has announced the presentation of data from the treatment phase of its CATALYST trial at the American Diabetes Association's 85th Scientific Sessions, with simultaneous publication in Diabetes Care. The trial, assessing the effects of the cortisol modulator Korlym® in patients with hypercortisolism and difficult-to-control type 2 diabetes, demonstrated significant improvements in glucose control, body weight, and waist circumference, while reducing the need for glucose-lowering medications. The CATALYST trial, which is the largest and most rigorous to date for this purpose, initially identified hypercortisolism in 24% of the 1,057 patients screened. The treatment phase involved 136 patients randomized to receive either Korlym or a placebo over 24 weeks. Results from this phase have already been presented.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。